$%^STN;HighlightOn= ***;HighlightOff=*** ;

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSPTAIAG1615

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * Welcome to STN International * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	DEC 01	ChemPort single article sales feature unavailable
NEWS 3	APR 03	CAS coverage of exemplified prophetic substances enhanced
NEWS 4	APR 07	STN is raising the limits on saved answers
NEWS 5	APR 24	CA/CAplus now has more comprehensive patent assignee information
NEWS 6	APR 26	USPATFULL and USPAT2 enhanced with patent assignment/reassignment information
NEWS 7	APR 28	CAS patent authority coverage expanded
NEWS 8	APR 28	ENCOMPLIT/ENCOMPLIT2 search fields enhanced
NEWS 9	APR 28	Limits doubled for structure searching in CAS REGISTRY
NEWS 10	MAY 08	STN Express, Version 8.4, now available
NEWS 11	MAY 11	STN on the Web enhanced
NEWS 12	MAY 11	BEILSTEIN substance information now available on STN Easy
NEWS 13	MAY 14	DGENE, PCTGEN and USGENE enhanced with increased limits for exact sequence match searches and introduction of free HIT display format
NEWS 14	MAY 15	INPADOCDB and INPAFAMDB enhanced with Chinese legal status data
NEWS 15	MAY 28	CAS databases on STN enhanced with NANO super role in records back to 1992
NEWS 16	JUN 01	CAS REGISTRY Source of Registration (SR) searching enhanced on STN
NEWS 17	JUN 26	NUTRACEUT and PHARMAML no longer updated
NEWS 18	JUN 29	IMSCOPROFILE now reloaded monthly
NEWS 19	JUN 29	EPFULL adds SLART to AB, MCLM, and TI fields
NEWS EXPRESS	MAY 26 09	CURRENT WINDOWS VERSION IS V8.4, AND CURRENT DISCOVER FILE IS DATED 06 APRIL 2009.
NEWS HOURS		STN Operating Hours Plus Help Desk Availability
NEWS LOGIN		Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.

and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 13:47:50 ON 07 JUL 2009

=> file registry
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 0.22 0.22

FILE 'REGISTRY' ENTERED AT 13:48:07 ON 07 JUL 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem

STRUCTURE FILE UPDATES: 6 JUL 2009 HIGHEST RN 1160908-15-5
DICTIONARY FILE UPDATES: 6 JUL 2009 HIGHEST RN 1160908-15-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> s polyethyleneimine OR polyethylenimine OR "poly ethyleneimine" OR "polyethylene
imine" OR "poly ethylene imine" OR pei
16 POLYETHYLENEIMINE
64 POLYETHYLENIMINE
1977124 "POLY"
119 "ETHYLENEIMINE"
19 "POLY ETHYLENEIMINE"
("POLY"(W)"ETHYLENEIMINE")
10233 "POLYETHYLENE"
43546 "IMINE"
2 "IMINES"
43546 "IMINE"
("IMINE" OR "IMINES")
16 "POLYETHYLENE IMINE"
("POLYETHYLENE"(W)"IMINE")
1977124 "POLY"
108445 "ETHYLENE"
2 "ETHYLENES"
108445 "ETHYLENE"
("ETHYLENE" OR "ETHYLENES")
43546 "IMINE"
2 "IMINES"
43546 "IMINE"
("IMINE" OR "IMINES")
19 "POLY ETHYLENE IMINE"
("POLY"(W)"ETHYLENE"(W)"IMINE")
78 PEI

```
             1 PEIS
            79 PEI
               (PEI OR PEIS)
L1         157 POLYETHYLENEIMINE OR POLYETHYLENIMINE OR "POLY ETHYLENEIMINE"
               OR "POLYETHYLENE IMINE" OR "POLY ETHYLENE IMINE" OR PEI

=> file caplus
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                        54.46      54.68

FILE 'CAPLUS' ENTERED AT 13:49:08 ON 07 JUL 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 7 Jul 2009  VOL 151 ISS 2
FILE LAST UPDATED: 6 Jul 2009  (20090706/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED:  Apr 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE:  Apr 2009

CAplus now includes complete International Patent Classification (IPC)
reclassification data for the second quarter of 2009.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> s L1
L2         30236 L1

=> s L2 AND uchegbu/AU
             0 UCHEGBU/AU
L3           0 L2 AND UCHEGBU/AU

=> s uchegbu
L4           5 UCHEGBU

=> d scan L4

L4    5 ANSWERS   CAPLUS  COPYRIGHT 2009 ACS on STN
CC    63-6 (Pharmaceuticals)
      Section cross-reference(s): 38
TI    A non-covalently crosslinked chitosan based hydrogel
ST    crosslinked glycol chitosan hydrogel
IT    Drug delivery systems
         (hydrogels; non-covalently crosslinked chitosan based hydrogel)
IT    57-10-3DP, Palmitic acid, reaction products with glycol chitosan
      9012-76-4DP, Chitosan, crosslinked  123938-86-3DP, Glycol Chitosan,
```

```
     crosslinked
     RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use);
     BIOL (Biological study); PREP (Preparation); USES (Uses)
        (non-covalently crosslinked chitosan based hydrogel)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):3

L4    5 ANSWERS   CAPLUS  COPYRIGHT 2009 ACS on STN
TI   I.F.   ***Uchegbu***  . Polymers in Drug Delivery, edited by, A.G.
     Schatzlein. CRC Press, Boca Raton, FL, USA (2006)

L4    5 ANSWERS   CAPLUS  COPYRIGHT 2009 ACS on STN
TI   Review of Synthetic Surfactant Vesicles Edited by I.F.   ***Uchegbu***  ,
     Harwood Academic Publishers, Amsterdam, 2000. 248 pp

L4    5 ANSWERS   CAPLUS  COPYRIGHT 2009 ACS on STN
CC   1-6 (Pharmacology)
TI   The activity of doxorubicin niosomes against an ovarian cancer cell line
     and three in vivo mouse tumor models
ST   antitumor doxorubicin sorbitan monostearate niosome
IT   Neoplasm inhibitors
        (activity of doxorubicin niosomes against an ovarian cancer cell line
        and three in vivo mouse tumor models)
IT   Liposome
        (niosome, activity of doxorubicin niosomes against an ovarian cancer
        cell line and three in vivo mouse tumor models)
IT   1338-41-6, Sorbitan monostearate
     RL: BUU (Biological use, unclassified); BIOL (Biological study); USES
     (Uses)
        (activity of doxorubicin niosomes against an ovarian cancer cell line
        and three in vivo mouse tumor models)
IT   23214-92-8, Doxorubicin
     RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
        (activity of doxorubicin niosomes against an ovarian cancer cell line
        and three in vivo mouse tumor models)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):
HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> s uchegbu/au
L5            0 UCHEGBU/AU

=> d hist

     (FILE 'HOME' ENTERED AT 13:47:50 ON 07 JUL 2009)

     FILE 'REGISTRY' ENTERED AT 13:48:07 ON 07 JUL 2009
L1          157 S POLYETHYLENEIMINE OR POLYETHYLENIMINE OR "POLY ETHYLENEIMINE"

     FILE 'CAPLUS' ENTERED AT 13:49:08 ON 07 JUL 2009
L2        30236 S L1
L3            0 S L2 AND UCHEGBU/AU
L4            5 S UCHEGBU
L5            0 S UCHEGBU/AU

=> s L2 AND L4
L6            0 L2 AND L4

=> s L2 AND "drug delivery"
        874898 "DRUG"
        384122 "DRUGS"
       1056821 "DRUG"
                ("DRUG" OR "DRUGS")
```

```
         335121 "DELIVERY"
           2054 "DELIVERIES"
         336359 "DELIVERY"
                  ("DELIVERY" OR "DELIVERIES")
         237011 "DRUG DELIVERY"
                  ("DRUG"(W)"DELIVERY")
L7         1184 L2 AND "DRUG DELIVERY"

=> s L7 AND "qcpei"
              0 "QCPEI"
L8            0 L7 AND "QCPEI"

=> s L7 AND "qcpei1"
              0 "QCPEI1"
L9            0 L7 AND "QCPEI1"

=> s L7 AND qcpei
=> s L7 AND qcpei
=> s (cyclosporin OR "Cyclosporin")
          18374 CYCLOSPORIN
            404 CYCLOSPORINS
          18415 CYCLOSPORIN
                  (CYCLOSPORIN OR CYCLOSPORINS)
          18374 "CYCLOSPORIN"
            404 "CYCLOSPORINS"
          18415 "CYCLOSPORIN"
                  ("CYCLOSPORIN" OR "CYCLOSPORINS")
L10       18415 (CYCLOSPORIN OR "CYCLOSPORIN")

=> s L7 AND L10
L11           16 L7 AND L10

=> d L11 1- ibib abs
YOU HAVE REQUESTED DATA FROM 16 ANSWERS - CONTINUE? Y/(N):y

L11  ANSWER 1 OF 16  CAPLUS  COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER:          2009:182624  CAPLUS <<LOGINID::20090707>>
DOCUMENT NUMBER:           150:290644
TITLE:                     Sustained-release microcapsule of protein polypeptide
                           drug and its preparation method
INVENTOR(S):               Dai, Zhifei; Yue, Xiuli; Zheng, Jian; Liu, Shaoqin;
                           Wang, Yang; Yan, Xiufeng
PATENT ASSIGNEE(S):        Harbin Institute of Technology, Peop. Rep. China
SOURCE:                    Faming Zhuanli Shenqing Gongkai Shuomingshu, 21pp.
                           CODEN: CNXXEV
DOCUMENT TYPE:             Patent
LANGUAGE:                  Chinese
FAMILY ACC. NUM. COUNT:    1
PATENT INFORMATION:

     PATENT NO.            KIND   DATE         APPLICATION NO.          DATE
     ----------------      ----   --------     --------------------     --------
     CN 101361963           A     20090211     CN 2008-10137122         20080916
PRIORITY APPLN. INFO.:                         CN 2008-10137122         20080916
AB   The prepn. method comprises (1) dissolving protein polypeptide drug in
     0.001-100 mmol/L HCl at a ratio of (0.01-100) mg: 1 mL, adjusting the pH
     to 1-7, adding inorg. salt till its concn. is 0.01-10 mol/L, stirring at a
     speed of 10-600 r/min for 0.1-100 min, ultrasonic processing for 0.01-100
     min, centrifugating or filtering to obtain particles of protein
     polypeptide drug; (2) dissolving polyanion in 0.01-10 mol/L inorg. salt,
     adjusting the pH to 1-7, adding particles of protein polypeptide drug,
     stirring, carrying out adsorption reaction for 0.1-100 min, ultrasonic
     processing for 0.01-100 min, centrifugating or filtering, washing solid
```

phase; (3) adding treated particles of protein polypeptide drug into polyvalent metal cation (0.1-100 mg/mL, pH 1-7), stirring, carrying out adsorption reaction for 0.1-100 min, ultrasonic processing for 0.01-100 min, centrifugating or filtering, washing; (4) repeating step (3) once; and (5) dissolving polycation in 0.01-10 mol/L inorg. salt, adjusting the pH to 1-7, adding particles of protein polypeptide drug from step (4), stirring, carrying out adsorption reaction for 0.1-100 min, ultrasonic processing for 0.01-100 min, centrifugating or filtering, and washing to obtain the product. The protein polypeptide drug is insulin, interferon, hirudin, calcitonin, growth hormone, etc. The polyanion is sodium alginate, glucose, dextran sulfate, heparin, etc. The inorg. salt is NaCl, NH4Cl, (NH4)2SO4, KCl, etc. The polyvalent metal cation is Zn2+, Cu2+, Fe3+, Ru3+, Os3+, etc. The polycation is chitosan, protamine, polyarginine, polyethylenimine, etc. The microcapsule provided in this invention has improved stability, biol. activity and sustained-release characteristic, and can supply trace elements for human body.

L11 ANSWER 2 OF 16 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2009:24490 CAPLUS <<LOGINID::20090707>>
DOCUMENT NUMBER: 150:142453
TITLE: MHC multimers and conjugates for use in diagnosis, prognosis and therapy of cancer, infection, immune and autoimmune disease
INVENTOR(S): Brix, Liselotte; Pedersen, Henrik; Jakobsen, Tina; Schoeller, Joergen; Lohse, Jesper; Brunstedt, Katja; Jacobsen, Kivin
PATENT ASSIGNEE(S): Dako Denmark A/S, Den.
SOURCE: PCT Int. Appl., 470pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009003492	A1	20090108	WO 2008-DK50167	20080703
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.:		
DK 2007-972	A	20070703
DK 2007-973	A	20070703
DK 2007-974	A	20070703
DK 2007-975	A	20070703
US 2007-929581P	P	20070703
US 2007-929582P	P	20070703
US 2007-929583P	P	20070703
US 2007-929586P	P	20070703

AB The present invention describes novel methods to generate MHC or HLA multimers and methods to improve existing and new MHC multimers. The invention also describes improved methods for the use of MHC multimers in anal. of T-cells in samples 5 including diagnostic and prognostic methods. Furthermore the use of MHC multimers in therapy are described, e.g. anti-tumor and anti-virus therapy, including isolation of antigen specific

T-cells capable of inactivation or elimination of undesirable target cells or isolation of specific T-cells capable of regulation of other immune cells.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 3 OF 16 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2008:1508205 CAPLUS <<LOGINID::20090707>>
DOCUMENT NUMBER: 150:56994
TITLE: Poly(organophosphazene) hydrogels for ***drug*** ***delivery*** , preparation method thereof and use thereof
INVENTOR(S): Song, Soo-Chang; Park, M-Ran; Lee, Sun-M
PATENT ASSIGNEE(S): Korea Institute of Science and Technology, S. Korea
SOURCE: PCT Int. Appl., 88pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008153277	A1	20081218	WO 2008-KR2715	20080523
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
KR 2008110472	A	20081218	KR 2008-40413	20080430
US 20090047348	A1	20090219	US 2008-122665	20080517
PRIORITY APPLN. INFO.:			KR 2007-58461 A	20070614
			KR 2008-40413 A	20080430
			WO 2008-KR2715 A	20080523

AB A biodegradable and thermosensitive poly(organophosphazene) with a functional group, a prepn. method thereof, and a use thereof for delivery of bioactive substances are provided.

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 4 OF 16 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2008:1339197 CAPLUS <<LOGINID::20090707>>
DOCUMENT NUMBER: 149:534721
TITLE: Polyglutamic acids functionalized by cation groups and hydrophobic groups, and their therapeutic applications
INVENTOR(S): Chan, You Ping; Breyne, Olivier; Bonnet Gonnet, Cecile
PATENT ASSIGNEE(S): Flamel Technologies, Fr.
SOURCE: Fr. Demande, 43pp.
CODEN: FRXXBL
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

FR 2915748 A1 20081107 FR 2007-3185 20070503
WO 2008135563 A1 20081113 WO 2008-EP55507 20080505
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
US 20090012028 A1 20090108 US 2008-149542 20080505
PRIORITY APPLN. INFO.: FR 2007-3185 A 20070503
US 2007-924218P P 20070503

AB Polyglutamates for use in ***drug*** ***delivery*** are manufd. by forming cation groups which, if they are deprotonables, present a pKa equal to or higher than 7, and by hydrophobic groupings comprising from 8 to 30 carbon atoms. These polyglutamates modified by cation groups are ready to be transformed easily and economically into particles of vectorization of active principles, these particles being themselves clean to form stable aq. colloidal suspensions. These polyglutamates modified has the advantage of being less viscous than other similar polymers, while preserving a capacity to assoc. proteins such as insulin. Some are water-sol. with acid pH and become insol. with physiol. pH (7,4) and would thus have, at the time of a s.c. injection, to ppt. on the site of injection. A typical polymer was manufd. by stirring 6 g polyglutamic acid grafted with 5%.alpha.-tocopherol 15 min at 0.degree. in 125 mL DMF contg. 8.7 mL iso-Bu chloroformate, adding suspension of 24.67 g argininamide dihydrochloride in 308 mL NMP contg. 14.7 mL Et3N at 0.degree., stirring 2 h at 0.degree., adding 2.1 mL 35% aq. HCl, and adding the resulting reaction mixt. to 1.6 L water.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2008:1156621 CAPLUS <<LOGINID::20090707>>
DOCUMENT NUMBER: 149:409737
TITLE: Topical formulations comprising lipophilic bioactive agents having enhanced bioavailability
INVENTOR(S): McCook, John Patrick; Narain, Niven Rajin; Persaud, Indushekhar
PATENT ASSIGNEE(S): Pathfinder Management, Inc., USA
SOURCE: PCT Int. Appl., 68pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE
WO 2008116135 A2 20080925 WO 2008-US57786 20080321
WO 2008116135 A3 20081224
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

US 20080233183 A1 20080925 US 2008-52825 20080321
PRIORITY APPLN. INFO.: US 2007-919554P P 20070322

AB The present disclosure provides compns. suitable for delivering lipophilic bioactive agents. The compns. may be utilized to treat numerous diseases and conditions that would benefit from the application of a lipophilic bioactive agent. Thus, a cream contained Polysorbate-80 25.000, ubidecarenone 21.000, propylene glycol 10.000, phenoxyethanol 0.500, water 35.500, and lecithin 8.000%

L11 ANSWER 6 OF 16 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2008:1067724 CAPLUS <<LOGINID::20090707>>
DOCUMENT NUMBER: 149:315743
TITLE: Coated expandable system comprising a catheter balloon and a crimped stent for the controlled release of drugs
INVENTOR(S): Orlowski, Michael
PATENT ASSIGNEE(S): Germany
SOURCE: Ger. Offen., 17pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 102007008479	A1	20080904	DE 2007-102007008479	20070221
WO 2008101486	A2	20080828	WO 2008-DE301	20080220

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: DE 2007-102007008479A 20070221
US 2007-903298P P 20070226

AB The invention relates to an expandable system comprising a catheter balloon and a crimped stent. Said system combines fast-release kinetics of one active substance and slow-release kinetics of a second active substance since the catheter balloon is coated with a first active substance that is suitable for fast release while the stent is coated with a second active substance which is suitable for slow release. In a preferred embodiment, the catheter balloon is coated with a cytotoxic amt. of a first active substance while the stent is coated with a cytostatic amt. of a second active substance.
REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2008:1045421 CAPLUS <<LOGINID::20090707>>
DOCUMENT NUMBER: 149:315698
TITLE: Coated expandable system comprising a catheter balloon

and a crimped stent for the controlled release of drugs
INVENTOR(S): Orlowski, Michael
PATENT ASSIGNEE(S): Eurocor G.m.b.H., Germany
SOURCE: PCT Int. Appl., 29pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008101486	A2	20080828	WO 2008-DE301	20080220
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
DE 102007008479	A1	20080904	DE 2007-102007008479	20070221
PRIORITY APPLN. INFO.:			DE 2007-102007008479A	20070221
			US 2007-903298P P	20070226

AB The invention relates to an expandable system comprising a catheter balloon and a crimped stent. Said system combines fast release kinetics of one active substance and slow release kinetics of a second active substance since the catheter balloon is coated with a first active substance that is suitable for fast release while the stent is coated with a second active substance which is suitable for slow release. In a preferred embodiment, the catheter balloon is coated with a cytotoxic amt. of a first active substance while the stent is coated with a cytostatic amt. of a second active substance.

L11 ANSWER 8 OF 16 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2007:937423 CAPLUS <<LOGINID::20090707>>
DOCUMENT NUMBER: 147:269264
TITLE: Cholesterol esterification pathway modulators and antiproliferative and anti-protein misfolding agents for the prophylactic and/or therapeutic treatment of proliferative and conformational diseases
INVENTOR(S): La Colla, Paolo; Anchisi, Carlo; Dessi, Sandra; Pani, Alessandra
PATENT ASSIGNEE(S): Italy
SOURCE: PCT Int. Appl., 48pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007094026	A1	20070823	WO 2007-IT109	20070219
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK,				

MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO,
RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT,
TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM

IT 2006RM0286 A1 20060829 IT 2006-RM286 20060529
PRIORITY APPLN. INFO.: US 2006-774311P P 20060217
IT 2006-RM286 A 20060529

AB The invention discloses the use of compds. modulating the pathways leading to cholesterol esterification for the prepn. of a medicament for the treatment and/or prevention of proliferative and/or conformational diseases or of early aging. The medicament further comprises a compd. endowed with antiproliferative and/or anti- protein misfolding activity.

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 9 OF 16 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2007:816913 CAPLUS <<LOGINID::20090707>>
DOCUMENT NUMBER: 147:220046
TITLE: Biodegradable and thermosensitive poly(organophosphazene) hydrogel, preparation method thereof and use thereof
INVENTOR(S): Song, Soo-Chang; Lee, Sun-M; Kim, Chang-Won; Park, M-Ran
PATENT ASSIGNEE(S): Korea Institute of Science and Technology, S. Korea
SOURCE: PCT Int. Appl., 87pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007083875	A2	20070726	WO 2006-KR4573	20061103
WO 2007083875	A3	20070907		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
KR 2007076386	A	20070724	KR 2006-107230	20061101
KR 784485	B1	20071211		
CA 2637285	A1	20070726	CA 2006-2637285	20061103
EP 1981544	A2	20081022	EP 2006-812410	20061103
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
US 20090022683	A1	20090122	US 2006-568851	20061108
CN 101360513	A	20090204	CN 2006-80051281	20080717

PRIORITY APPLN. INFO.:
KR 2006-5579 A 20060118
KR 2006-30730 A 20060404
KR 2006-107230 A 20061101
WO 2006-KR4573 W 20061103

GI

/ Structure 1 in file .gra /

AB The present invention relates to a biodegradable and thermosensitive poly(organophosphazene) with a functional group, a prepn. method thereof, and a use thereof for delivery of bioactive substances. According to the present invention, poly(organophosphazene) is a phosphagen-based polymer showing biodegradability, thermosensitivity, and sol-gel phase transition depending on temp. change, whereby when administered into a living body with bioactive substances such as drugs, the poly(organophosphazene) forms a gel-phase at body temp. to be capable of controlled release of the bioactive substances. Further, the poly(organophosphazene) has functional groups to chem. bind with bioactive substances through an ionic bond, covalent bond, or coordinate covalent bond to be capable of a sustained release of the bioactive substances due to its good binding property. The poly(organophosphazene) is represented as in Formula I, wherein p is an integer between 7 and 50; R1 is selected from the group consisting of H, HCH2, CH3, CH2SH, CH(CH3)2, CH2CH(CH3)2, CH(CH3)C2H5, CH2CH2SCH3, CH2C6H5, CH2C6H4OH, CH2C2NH2C6H4, CCCC4N+H9, CO2C2H5, CH2CO2C2Hs, (CH2)2CO2C2H5, and HCONHCH(CH2C6Hs), and R2 is selected from the group consisting of CH3, C3H7, C4H9, C2H5, CH2C6Hs, and CH2CHCH2; R3 is CH(W); R4 is selected from the group consisting of CO2, CO2CH2CO2, CO2CH(CH3)CO2, and CONHCH(X)CO2; R5 is selected from the group consisting of H, CH3, and C2H5, and W and X are independently selected from the group consisting of H, HCH2, CH3, CH(CH3)2, CH2CH(CH3)2, CH(CH3)C2H5, CH2CH2SCH3, CH2C6Hs, CH2C2NH2C6H4, CCCC4N+H9, CO2C2H5, (CH2)2CO2C2H5, CH2OH, CH(CH3)OH, CH2C6H4OH, CH2CCOH, CH2CH2CCOH, CH2CONH2, C4H8NH2, C3H6NHC(=NH)NH2, CH2C3N2H3, and CH2SH; R6 is CH(Y); R7 is selected from the group consisting of C2H4, C3H6, C4H8, CH2C6H4, CH2CO2, O, CONHCH(Z)O, CO, CO2, S, CONHCH(Z)S, N, CONHCH(Z)N, CON, CCCHNH(Z)CON, CONHCH(Z)CO, and CONHCH(Z)CO2; R8 is selected from the group consisting of OH, SH, H, CH3, C2H5, C3H7, C4H9, CH2C6H5, CH2CHCH2, and protecting groups. Also, Y and Z are independently selected from the group consisting of H, HCH2, CH3, CH(CH3)2, CH2CH(CH3)2, CH(CH3)C2H5, CH2CH2SCH3, CH2C6Hs, CH2C2NH2C6H4, CCCC4N+Hg, CO2C2H5, (CH2)2CO2C2H5, CH2OH, CH(CH3)OH, CH2C6H4OH, CH2CCOH, CH2CH2CCOH, CH2CONH2, C4H8NH2, C3H6NHC(=NH)NH2, CH2C3N2H3, and CH2SH; R9 is selected from the group consisting of OH, SH, H, NH2, CH3, C2H5, C3H7, C4H9, CH2C6Hs, CH2CHCH2, NHCH(SH)CO2H, NH(CH2)qSH, NH(CH2CH2NH)rH, [NHCH(C4H8NH2)CO]rOH, [NHCH[(CH2)3C(=NH)(NH2)]CO]rOH, and protamines; q is an integer between 1 and 20; r is an integer between 1 and 18000; a1, a2, b, c, d, and e resp. represent the content of each substituent, wherein a1, a2, b, and d are independently from 0.01 to 1.9, c and e are independently from 0 to 1.9, and a1 + a2 + b + c + d + e = 2.0; and n is from 5 to 100000. Therefore, the poly(organophosphazene) is useful as a delivery material for bioactive substances.

L11 ANSWER 10 OF 16 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2006:818283 CAPLUS <<LOGINID::20090707>>
DOCUMENT NUMBER: 145:218038
TITLE: Colonic delivery of agents that inactivate antibiotics
INVENTOR(S): Fattal, Elias; Andremont, Antoine; Couvreur, Patrick; Bourgeois, Sandrine
PATENT ASSIGNEE(S): Da Volterra, Fr.; Centre National De La Recherche Scientifique; Stevens, Ian Edward
SOURCE: PCT Int. Appl., 63pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006085075	A2	20060817	WO 2006-GB448	20060209
WO 2006085075	A3	20070830		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
AU 2006211996	A1	20060817	AU 2006-211996	20060209
CA 2595526	A1	20060817	CA 2006-2595526	20060209
EP 1845948	A2	20071024	EP 2006-709686	20060209
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
JP 2008529996	T	20080807	JP 2007-553714	20060209
IN 2007KN03118	A	20071228	IN 2007-KN3118	20070823
CN 101128187	A	20080220	CN 2006-80005835	20070823
US 20080317666	A1	20081225	US 2008-628832	20080303
PRIORITY APPLN. INFO.:			US 2005-651342P	P 20050209
			WO 2006-GB448	W 20060209

AB ***Drug*** ***delivery*** devices that are orally administered, and that release active ingredients in the colon, are disclosed. The active ingredients are those that inactivate antibiotics, such as macrolides, quinolones and beta-lactam contg. antibiotics. One example of a suitable active agent is an enzyme such as beta-lactamases. In another embodiment, the active agents are those that specifically treat colonic disorders, such as Crohn's Disease, irritable bowel syndrome, ulcerative colitis, colorectal cancer or constipation. The ***drug*** ***delivery*** devices are in the form of beads of pectin, crosslinked with calcium and reticulated with polyethyleneimine. The high crosslink d. of the polyethyleneimine is believed to stabilize the pectin beads for a sufficient amt. of time such that a substantial amt. of the active ingredients can be administered directly to the colon. Advantageously, the amt. of polyethyleneimine is sufficient to allow a substantial portion of the pectin beads to pass through the gastrointestinal tract to the colon without releasing the active agent, and is also sufficient such that the pectin beads are sufficiently degraded in the colon to release an effective amt. of the active agent.

L11 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:961492 CAPLUS <<LOGINID::20090707>>
DOCUMENT NUMBER: 143:254076
TITLE: Drug eluting coatings for medical implants and methods of use
INVENTOR(S): Hsu, Li-Chien
PATENT ASSIGNEE(S): Biotegra, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 9 pp., Cont.-in-part of U.S. Ser. No. 423,718.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20050191333	A1	20050901	US 2005-119075	20050428
US 20040037886	A1	20040226	US 2003-423718	20030426
US 7438925	B2	20081021		

PRIORITY APPLN. INFO.: US 2002-405933P P 20020826
US 2003-423718 A2 20030426

AB A drug coating for a medical device comprises one or more drug composite layers. The drug composite layer comprises one or more therapeutic agents dispersed within one or more modified bioactive binders. The modified bioactive binders are hydrophobic compds. bonded to bioactive binders, and the modified bioactive binders are not inert polymers.

L11 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:904325 CAPLUS <<LOGINID::20090707>>
DOCUMENT NUMBER: 143:241967
TITLE: Directed apoptosis in cox-2 overexpressing cancer cells through targeted gene delivery of apoptosis-inducing genes for tumor therapy
INVENTOR(S): Godbey, W Terrance; Atala, Anthony
PATENT ASSIGNEE(S): Children's Medical Center Corporation, USA
SOURCE: U.S. Pat. Appl. Publ., 32 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20050187177	A1	20050825	US 2004-23020	20041223

PRIORITY APPLN. INFO.: US 2004-533965P P 20040102

AB The present invention provides methods and constructs for selectively expressing an Apoptosis-Inducing Gene (AIG) in a population of tumor cells that overexpress cyclooxygenase-2 (COX-2) to induce apoptosis in the cell. To achieve this goal a chimeric gene construct is used that comprises a cyclooxygenase-2 promoter (COX-2 promoter) that is operably linked to at least one AIG such that the COX-2 promoter is activated in cells that overexpress COX-2, thereby resulting in transcription and translation of the AIG, which in turn activates apoptosis in the cell. Thus, apoptosis is selectively induced in only those cells capable of overexpressing COX-2. The apoptosis-inducing gene is selected from the group consisting of Caspase-1, Caspase-2, Caspase-3, Caspase-4, Caspase-5, Caspase-6, Caspase-7, Caspase-8, Caspase-9, Caspase-10, Granzyme A, Granzyme B, Fas ligand, TRAIL and APO3L.

L11 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:267381 CAPLUS <<LOGINID::20090707>>
DOCUMENT NUMBER: 140:309343
TITLE: Oral ***drug*** ***delivery*** systems for poorly soluble drugs using amphiphilic polyethylenimine polymers with solubilizing and absorption enhancing properties
INVENTOR(S): Uchegbu, Ijeoma; Schatzlein, Andreas; Cheng, Wbei Ping
PATENT ASSIGNEE(S): The University of Strathclyde, UK; The University Court of the University of Glasgow
SOURCE: PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004026941	A1	20040401	WO 2003-GB4036	20030922
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2499681	A1	20040401	CA 2003-2499681	20030922
AU 2003267581	A1	20040408	AU 2003-267581	20030922
EP 1543063	A1	20050622	EP 2003-748273	20030922
EP 1543063	B1	20090325		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006500437	T	20060105	JP 2004-537295	20030922
AT 426635	T	20090415	AT 2003-748273	20030922
US 20060148982	A1	20060706	US 2005-528602	20050929

PRIORITY APPLN. INFO.: GB 2002-21942 A 20020920
WO 2003-GB4036 W 20030922

AB This invention relates to the delivery of drugs. In particular, this invention relates to the oral delivery of poorly sol. drugs using novel amphiphilic polymers with both solubilizing and absorption enhancing properties. A polyethylenimine polymer according to the present invention wherein monomeric subunits in accordance with the structure is defined in formula [NHCH2CH2]m[N(Z)2CH2CH2]n[N(CH2CH2NH2)CH2CH2]p[N(Z)(CH2CH2NH2)CH2CH2]q[N(CH2CH2N(R1)(R2)(R3))CH2CH2]u[N(CH2CH2N(R1)(R2)(R3))CH2CH2]v[N(CH2CH2N(A)H)CH2CH2]w[N(Z)(CH2CH2N(A)H)CH2CH2]x[N(CH2CH2N(R1)(R2))CH2CH2]y[N(Z)(CH2CH2N(A)(R1)(R2))CH2CH2] wherein m=0-90%; n=0-100%; p=0-50%; q=0-50%; u=0-50%; v=0-50%; w=0-20%; x=0-20%; y=0-20%; z=0-20%; wherein, m+n+p+q+u+v+w+x+y+z=100%; Z=alkyl, alkenyl, alkynyl, etc; A=alkyl, alkenyl, alkynyl, etc; R1=alkyl, alkenyl, alkynyl, etc; R2=alkyl, alkenyl, alkynyl, etc; R3=alkyl, alkenyl, alkynyl, etc.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 14 OF 16 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2003:532709 CAPLUS <<LOGINID::20090707>>
DOCUMENT NUMBER: 139:101420
TITLE: Dendritic poly(amino acid) carrier conjugates with pharmaceuticals
INVENTOR(S): Li, Chun; Vega, Javier; Wallace, Sidney; Tansey, Wayne; Charnsangavej, Chusilp
PATENT ASSIGNEE(S): Board of Regents, the University of Texas System, USA
SOURCE: PCT Int. Appl., 105 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003055935	A1	20030710	WO 2002-US40937	20021223
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,				

LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA,
UG, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ,
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 20030232968	A1	20031218	US 2002-327455 20021220
US 7261875	B2	20070828	
CA 2469946	A1	20030710	CA 2002-2469946 20021223
AU 2002361821	A1	20030715	AU 2002-361821 20021223
EP 1465938	A1	20041013	EP 2002-797454 20021223

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK

PRIORITY APPLN. INFO.:	US 2001-342807P	P 20011221
	US 2002-327455	A 20021220
	WO 2002-US40937	W 20021223

AB The invention concerns a design for dendritic poly(amino acid) polymer carriers, also known as nonlinear polymers, and their applications. These dendritic poly(amino acid) carriers have multiple functional groups at the polymer surface and heterofunctional groups on the poly(amino acid) side chains for drug or diagnostic agent attachment. They are designed to allow sufficient preservation of the binding affinity of the targeting ligand while conjugating therapeutic or diagnostic agents to the polymers. The invention also describes methods of prodn. of the polymer carriers and methods for the treatment or diagnosis of diseases employing the polymer carriers. In an example, branched polyglutamic acids (PGs) PAMAM-PG [PAMAM is poly(amidoamine)denderimer] were prepd. and conjugated to paclitaxel (TXL). PAMAM-PG8-TXL and linear PG-TXL showed cytotoxicity IC50 = 20 nM in a human vulvar squamous A431 cell line (< 1.0 for the parent drug), suggesting that both conjugates behave as prodrugs.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 15 OF 16 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2002:716321 CAPLUS <<LOGINID::20090707>>
DOCUMENT NUMBER: 137:246527
TITLE: Multivalent MHC constructs: Immunoanalysis, diagnosis and therapy
INVENTOR(S): Wintther, Lars; Petersen, Lars Oestergaard; Buus, Soeren; Schoeller, Joergen; Ruub, Erik; Aamellem, Oeystein
PATENT ASSIGNEE(S): Dako A/S, Den.; Dynal Biotech Asa
SOURCE: PCT Int. Appl., 304 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002072631	A2	20020919	WO 2002-DK169	20020313
WO 2002072631	A3	20031106		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB,
GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA,

GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2440773	A1	20020919	CA 2002-2440773		20020313
AU 2002240818	A1	20020924	AU 2002-240818		20020313
AU 2002240818	B2	20080619			
EP 1377609	A2	20040107	EP 2002-706685		20020313
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
JP 2005500257	T	20050106	JP 2002-571544		20020313
NO 2003004020	A	20031106	NO 2003-4020		20030911
AU 2008202862	A1	20080724	AU 2008-202862		20080630
PRIORITY APPLN. INFO.:			DK 2001-435	A	20010314
			DK 2001-436	A	20010314
			DK 2001-441	A	20010314
			US 2001-275447P	P	20010314
			US 2001-275448P	P	20010314
			US 2001-275470P	P	20010314
			AU 2002-240818	A3	20020313
			WO 2002-DK169	W	20020313

AB The authors disclose MHC mol. constructs (classical and non-classical) conjugated to sol. or insol. carriers wherein the affinity and avidity of the constructs exceed that of comparable MHC tetramers. In one example, the construct is comprised of biotinylated HLA-A2 bound to FITC-labeled streptavidin conjugated to sol. derivatized dextran. The above construct loaded with MART-1 or influenza virus peptides was shown to effect T-cell activation at a lower concn. than. Also comprised by the present invention is the sample-mounted use of MHC mols., MHC mol. multimers, and MHC mol. constructs.

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 16 OF 16 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2000:209864 CAPLUS <<LOGINID::20090707>>
DOCUMENT NUMBER: 132:255982
TITLE: Method and system for enhancing delivery of peptides and proteins across the intestinal wall
INVENTOR(S): Brayden, David James; Gross, Joseph
PATENT ASSIGNEE(S): Elan Corp., PLC, Ire.
SOURCE: PCT Int. Appl., 73 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2000016741	A1	20000330	WO 1999-IE97		19990917
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM					
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
AU 9957572	A	20000410	AU 1999-57572		19990917
PRIORITY APPLN. INFO.:			IE 1998-780	A	19980921
			US 1998-100892P	P	19980923
			WO 1999-IE97	W	19990917

AB A system and method for enhancing the delivery of an agent, esp. peptides and proteins, across the intestinal wall of a mammal are disclosed. The system includes a device for applying a potential across the intestinal wall so as to enhance delivery of the agent. The device includes a pair

of electrodes and a power source. An agent may be located proximate to the intestinal wall sep. from the device or incorporated in the device. Elec. current is generated thereby enhancing delivery of the agent across the intestinal wall. The agent and the electrode may be incorporated into a swellable polymer. A schematic sectional side view of an orally administrable ***drug*** ***delivery*** device according to the invention is depicted. Use of iontophoresis to increase the transport of mannitol across rat colonic tissue in vitro is described.
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>
=> d hist

(FILE 'HOME' ENTERED AT 13:47:50 ON 07 JUL 2009)

FILE 'REGISTRY' ENTERED AT 13:48:07 ON 07 JUL 2009
L1 157 S POLYETHYLENEIMINE OR POLYETHYLENIMINE OR "POLY ETHYLENEIMINE"

FILE 'CAPLUS' ENTERED AT 13:49:08 ON 07 JUL 2009
L2 30236 S L1
L3 0 S L2 AND UCHEGBU/AU
L4 5 S UCHEGBU
L5 0 S UCHEGBU/AU
L6 0 S L2 AND L4
L7 1184 S L2 AND "DRUG DELIVERY"
L8 0 S L7 AND "QCPEI"
L9 0 S L7 AND "QCPEI1"
E CYCLOSPORIN+ALL/CT
L10 18415 S (CYCLOSPORIN OR "CYCLOSPORIN")
L11 16 S L7 AND L10

=> s quaternary (p) ammonium (p) (polyethyleneimine OR polyethylenimine OR "poly ethyleneimine" OR "polyethylene imine" OR "poly ethylene imine" OR pei)
148114 QUATERNARY
360 QUATERNARIES
148268 QUATERNARY
(QUATERNARY OR QUATERNARIES)
452031 AMMONIUM
452 AMMONIUMS
452189 AMMONIUM
(AMMONIUM OR AMMONIUMS)
4745 POLYETHYLENEIMINE
230 POLYETHYLENEIMINES
4838 POLYETHYLENEIMINE
(POLYETHYLENEIMINE OR POLYETHYLENEIMINES)
7865 POLYETHYLENIMINE
428 POLYETHYLENIMINES
7942 POLYETHYLENIMINE
(POLYETHYLENIMINE OR POLYETHYLENIMINES)
777822 "POLY"
2 "POLIES"
777823 "POLY"
("POLY" OR "POLIES")
2066 "ETHYLENEIMINE"
107 "ETHYLENEIMINES"
2138 "ETHYLENEIMINE"
("ETHYLENEIMINE" OR "ETHYLENEIMINES")
783 "POLY ETHYLENEIMINE"
("POLY"(W)"ETHYLENEIMINE")
408572 "POLYETHYLENE"
15554 "POLYETHYLENES"

```
          413378 "POLYETHYLENE"
                 ("POLYETHYLENE" OR "POLYETHYLENES")
           24646 "IMINE"
           17920 "IMINES"
           34897 "IMINE"
                 ("IMINE" OR "IMINES")
             497 "POLYETHYLENE IMINE"
                 ("POLYETHYLENE"(W)"IMINE")
          777822 "POLY"
               2 "POLIES"
          777823 "POLY"
                 ("POLY" OR "POLIES")
          601275 "ETHYLENE"
            3495 "ETHYLENES"
          602813 "ETHYLENE"
                 ("ETHYLENE" OR "ETHYLENES")
           24646 "IMINE"
           17920 "IMINES"
           34897 "IMINE"
                 ("IMINE" OR "IMINES")
             386 "POLY ETHYLENE IMINE"
                 ("POLY"(W)"ETHYLENE"(W)"IMINE")
            5650 PEI
             223 PEIS
            5722 PEI
                 (PEI OR PEIS)
L12          214 QUATERNARY(P) AMMONIUM(P) (POLYETHYLENEIMINE OR POLYETHYLENIMI
                 NE OR "POLY ETHYLENEIMINE" OR "POLYETHYLENE IMINE" OR "POLY ETHY
                 LENE IMINE" OR PEI)

=> s L7 AND L12
L13            3 L7 AND L12

=> d L13 1-
YOU HAVE REQUESTED DATA FROM 3 ANSWERS - CONTINUE? Y/(N):y

L13  ANSWER 1 OF 3  CAPLUS  COPYRIGHT 2009 ACS on STN
AN   2006:1108241  CAPLUS <<LOGINID::20090707>>
DN   145:495524
TI   Encapsulation of epigallocatechin gallate with polymers for stability
     improvement
IN   Kim, Chul Hwan; Lee, Sung Mahn
PA   Dpi Solutions, Inc., S. Korea
SO   Repub. Korean Kongkae Taeho Kongbo, No pp. given
     CODEN: KRXXA7
DT   Patent
LA   Korean
FAN.CNT 1
     PATENT NO.            KIND   DATE         APPLICATION NO.          DATE
     ---------------       ----   --------     --------------------     --------
PI   KR 2006028916          A      20060404     KR 2004-77823            20040930
PRAI KR 2004-77823                 20040930

L13  ANSWER 2 OF 3  CAPLUS  COPYRIGHT 2009 ACS on STN
AN   2006:378166  CAPLUS <<LOGINID::20090707>>
DN   144:495174
TI   Antibacterial activity of dental composites containing  ***quaternary***
       ***ammonium***     ***polyethylenimine***  nanoparticles against
     Streptococcus mutans
AU   Beyth, Nurit; Yudovin-Farber, Ira; Bahir, Ran; Domb, Abraham J.; Weiss,
     Ervin I.
CS   Department of Prosthodontics, Faculty of Dentistry, Hebrew University of
     Jerusalem, Jerusalem, Israel
```

SO Biomaterials (2006), 27(21), 3995-4002
CODEN: BIMADU; ISSN: 0142-9612
PB Elsevier Ltd.
DT Journal
LA English
RE.CNT 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2005:218239 CAPLUS <<LOGINID::20090707>>
DN 143:253612
TI Studies on adsorption properties of chemically modified chitosan resins to diuretics
AU Chen, Fei; Luo, Guangsheng; Wang, Yujun
CS State Key Lab of Chemical Engineering, Department of Chemical Engineering Tsinghua University, Beijing, 100084, Peop. Rep. China
SO Gaofenzi Xuebao (2005), (1), 53-59
CODEN: GAXUE9; ISSN: 1000-3304
PB Kexue Chubanshe
DT Journal
LA Chinese

=> s quaternary (p) (polyethyleneimine OR polyethylenimine OR "poly ethyleneimine" OR "polyethylene imine" OR "poly ethylene imine" OR pei)

```
        148114 QUATERNARY
           360 QUATERNARIES
        148268 QUATERNARY
                 (QUATERNARY OR QUATERNARIES)
          4745 POLYETHYLENEIMINE
           230 POLYETHYLENEIMINES
          4838 POLYETHYLENEIMINE
                 (POLYETHYLENEIMINE OR POLYETHYLENEIMINES)
          7865 POLYETHYLENIMINE
           428 POLYETHYLENIMINES
          7942 POLYETHYLENIMINE
                 (POLYETHYLENIMINE OR POLYETHYLENIMINES)
        777822 "POLY"
             2 "POLIES"
        777823 "POLY"
                 ("POLY" OR "POLIES")
          2066 "ETHYLENEIMINE"
           107 "ETHYLENEIMINES"
          2138 "ETHYLENEIMINE"
                 ("ETHYLENEIMINE" OR "ETHYLENEIMINES")
           783 "POLY ETHYLENEIMINE"
                 ("POLY"(W)"ETHYLENEIMINE")
        408572 "POLYETHYLENE"
         15554 "POLYETHYLENES"
        413378 "POLYETHYLENE"
                 ("POLYETHYLENE" OR "POLYETHYLENES")
         24646 "IMINE"
         17920 "IMINES"
         34897 "IMINE"
                 ("IMINE" OR "IMINES")
           497 "POLYETHYLENE IMINE"
                 ("POLYETHYLENE"(W)"IMINE")
        777822 "POLY"
             2 "POLIES"
        777823 "POLY"
                 ("POLY" OR "POLIES")
        601275 "ETHYLENE"
          3495 "ETHYLENES"
```

```
        602813 "ETHYLENE"
                 ("ETHYLENE" OR "ETHYLENES")
         24646 "IMINE"
         17920 "IMINES"
         34897 "IMINE"
                 ("IMINE" OR "IMINES")
           386 "POLY ETHYLENE IMINE"
                 ("POLY"(W)"ETHYLENE"(W)"IMINE")
          5650 PEI
           223 PEIS
          5722 PEI
                 (PEI OR PEIS)
L14        293 QUATERNARY (P) (POLYETHYLENEIMINE OR POLYETHYLENIMINE OR "POLY
               ETHYLENEIMINE" OR "POLYETHYLENE IMINE" OR "POLY ETHYLENE IMINE"
               OR PEI)

=> s L7 AND L14
L15            4 L7 AND L14

=> d hist

     (FILE 'HOME' ENTERED AT 13:47:50 ON 07 JUL 2009)

     FILE 'REGISTRY' ENTERED AT 13:48:07 ON 07 JUL 2009
L1           157 S POLYETHYLENEIMINE OR POLYETHYLENIMINE OR "POLY ETHYLENEIMINE"

     FILE 'CAPLUS' ENTERED AT 13:49:08 ON 07 JUL 2009
L2         30236 S L1
L3             0 S L2 AND UCHEGBU/AU
L4             5 S UCHEGBU
L5             0 S UCHEGBU/AU
L6             0 S L2 AND L4
L7          1184 S L2 AND "DRUG DELIVERY"
L8             0 S L7 AND "QCPEI"
L9             0 S L7 AND "QCPEI1"
               E CYCLOSPORIN+ALL/CT
L10        18415 S (CYCLOSPORIN OR "CYCLOSPORIN")
L11           16 S L7 AND L10
L12          214 S QUATERNARY (P) AMMONIUM (P) (POLYETHYLENEIMINE OR POLYETHYLEN
L13            3 S L7 AND L12
L14          293 S QUATERNARY (P) (POLYETHYLENEIMINE OR POLYETHYLENIMINE OR "POL
L15            4 S L7 AND L14

=> s L15 NOT L13
L16            1 L15 NOT L13

=> d L16 ibib abs

L16  ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER:          2005:3745  CAPLUS <<LOGINID::20090707>>
DOCUMENT NUMBER:           142:266552
TITLE:                     Cationic lipids with increased DNA binding affinity
                           for nonviral gene transfer in dividing and nondividing
                           cells
AUTHOR(S):                 Narang, Ajit S.; Thoma, Laura; Miller, Duane D.;
                           Mahato, Ram I.
CORPORATE SOURCE:          Departments of Pharmaceutical Sciences and Biomedical
                           Engineering, University of Tennessee Health Science
                           Center, Memphis, TN, 38163, USA
SOURCE:                    Bioconjugate Chemistry (2005), 16(1), 156-168
                           CODEN: BCCHES; ISSN: 1043-1802
PUBLISHER:                 American Chemical Society
DOCUMENT TYPE:             Journal
```

LANGUAGE: English
OTHER SOURCE(S): CASREACT 142:266552

AB Effect of headgroup structure on cationic lipid-mediated transfection was investigated with either a (i) tertiary amine, (ii) quaternary amine with a hydroxyl, or (iii) quaternary amine with mesylate as headgroups. Liposomes were formulated using cholesterol or dioleoyl phosphatidyl ethanolamine (DOPE) as colipids, and transfection efficiencies were detd. in rapidly dividing colon carcinoma (CT 26) and rat aortic smooth muscle (RASM) cells as well as in nondividing human pancreatic islets using luciferase and green fluorescent protein expression plasmids, pcDNA3-Luc and pCMS-EGFP, resp. Liposome/pDNA complexes were evaluated for DNA conformational state by CD, DNA condensation by electrophoretic mobility shift assay (EMSA), particle size and zeta potential by laser diffraction technique, and surface morphol. by transmission electron microscopy (TEM). Encouraging transfection results were obtained with the mesylate headgroup based lipid in liposome formulations with DOPE as a colipid, which were higher than the com available Lipofectamine formulation. We hypothesize that the addnl. hydrogen bonding or covalent interactions of the headgroup with the plasmid DNA, leading to higher binding affinity of the cationic lipids to pDNA, results in higher transfection. This hypothesis is supported by TEM observations where elongated complexes were obsd. and more lipid was seen assocd. with the DNA.

REFERENCE COUNT: 59 THERE ARE 59 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> s quater (p) (polyethyleneimine OR polyethylenimine OR "poly ethyleneimine" OR
"polyethylene imine" OR "poly ethylene imine" OR pei)
(P) IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s quatern (p) (polyethyleneimine OR polyethylenimine OR "poly ethyleneimine" OR
"polyethylene imine" OR "poly ethylene imine" OR pei)
(P) IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s quatern (p) (polyethyleneimine OR polyethylenimine OR "poly ethyleneimine" OR
"polyethylene imine" OR "poly ethylene imine" OR pei)
(P) IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s quatern
=> s quatern?
L17     162367 QUATERN?

=> s quatern? (p) (polyethyleneimine OR polyethylenimine OR "poly ethyleneimine" OR
"polyethylene imine" OR "poly ethylene imine" OR pei)
        162367 QUATERN?
          4745 POLYETHYLENEIMINE
           230 POLYETHYLENEIMINES
          4838 POLYETHYLENEIMINE
                 (POLYETHYLENEIMINE OR POLYETHYLENEIMINES)
          7865 POLYETHYLENIMINE
           428 POLYETHYLENIMINES
          7942 POLYETHYLENIMINE
                 (POLYETHYLENIMINE OR POLYETHYLENIMINES)
        777822 "POLY"
```

```
             2 "POLIES"
        777823 "POLY"
                 ("POLY" OR "POLIES")
          2066 "ETHYLENEIMINE"
           107 "ETHYLENEIMINES"
          2138 "ETHYLENEIMINE"
                 ("ETHYLENEIMINE" OR "ETHYLENEIMINES")
           783 "POLY ETHYLENEIMINE"
                 ("POLY"(W)"ETHYLENEIMINE")
        408572 "POLYETHYLENE"
         15554 "POLYETHYLENES"
        413378 "POLYETHYLENE"
                 ("POLYETHYLENE" OR "POLYETHYLENES")
         24646 "IMINE"
         17920 "IMINES"
         34897 "IMINE"
                 ("IMINE" OR "IMINES")
           497 "POLYETHYLENE IMINE"
                 ("POLYETHYLENE"(W)"IMINE")
        777822 "POLY"
             2 "POLIES"
        777823 "POLY"
                 ("POLY" OR "POLIES")
        601275 "ETHYLENE"
          3495 "ETHYLENES"
        602813 "ETHYLENE"
                 ("ETHYLENE" OR "ETHYLENES")
         24646 "IMINE"
         17920 "IMINES"
         34897 "IMINE"
                 ("IMINE" OR "IMINES")
           386 "POLY ETHYLENE IMINE"
                 ("POLY"(W)"ETHYLENE"(W)"IMINE")
          5650 PEI
           223 PEIS
          5722 PEI
                 (PEI OR PEIS)
L18        458 QUATERN? (P) (POLYETHYLENEIMINE OR POLYETHYLENIMINE OR "POLY
               ETHYLENEIMINE" OR "POLYETHYLENE IMINE" OR "POLY ETHYLENE IMINE"
               OR PEI)

=> d hist

     (FILE 'HOME' ENTERED AT 13:47:50 ON 07 JUL 2009)

     FILE 'REGISTRY' ENTERED AT 13:48:07 ON 07 JUL 2009
L1           157 S POLYETHYLENEIMINE OR POLYETHYLENIMINE OR "POLY ETHYLENEIMINE"

     FILE 'CAPLUS' ENTERED AT 13:49:08 ON 07 JUL 2009
L2         30236 S L1
L3             0 S L2 AND UCHEGBU/AU
L4             5 S UCHEGBU
L5             0 S UCHEGBU/AU
L6             0 S L2 AND L4
L7          1184 S L2 AND "DRUG DELIVERY"
L8             0 S L7 AND "QCPEI"
L9             0 S L7 AND "QCPEI1"
               E CYCLOSPORIN+ALL/CT
L10        18415 S (CYCLOSPORIN OR "CYCLOSPORIN")
L11           16 S L7 AND L10
L12          214 S QUATERNARY (P) AMMONIUM (P) (POLYETHYLENEIMINE OR POLYETHYLEN
L13            3 S L7 AND L12
L14          293 S QUATERNARY (P) (POLYETHYLENEIMINE OR POLYETHYLENIMINE OR "POL
```

```
L15             4 S L7 AND L14
L16             1 S L15 NOT L13
L17        162367 S QUATERN?
L18           458 S QUATERN? (P) (POLYETHYLENEIMINE OR POLYETHYLENIMINE OR "POLY

=> s L7 AND L18
L19             9 L7 AND L18

=> L19 NOT (L15)
L19 IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s L19 NOT (L15)
L20             5 L19 NOT (L15)

=> d L20 1- ibib abs
YOU HAVE REQUESTED DATA FROM 5 ANSWERS - CONTINUE? Y/(N):y

L20 ANSWER 1 OF 5  CAPLUS  COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER:          2007:410600  CAPLUS <<LOGINID::20090707>>
DOCUMENT NUMBER:           146:415130
TITLE:                     Methods and ion-binding core-shell particle
                           compositions for selectively removing potassium ion
                           from the gastrointestinal tract of a mammal
INVENTOR(S):               Cope, Michael J.; Mansky, Paul; Liu, Futian; Chang,
                           Han-Ting; Charmot, Dominique; Connor, Eric; Biyani,
                           Kalpesh; Liu, Mingjun; Mong, Tony Kwok-Kong; Chen, Yan
PATENT ASSIGNEE(S):        Ilypsa, Inc., USA
SOURCE:                    PCT Int. Appl., 173pp.
                           CODEN: PIXXD2
DOCUMENT TYPE:             Patent
LANGUAGE:                  English
FAMILY ACC. NUM. COUNT:    1
PATENT INFORMATION:

      PATENT NO.           KIND   DATE         APPLICATION NO.          DATE
      ---------------      ----   --------     --------------------     --------
      WO 2007041569         A1    20070412     WO 2006-US38602          20061002
           W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
              CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
              GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,
              KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN,
              MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS,
              RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ,
              UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
           RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
              IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
              CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
              GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
              KG, KZ, MD, RU, TJ, TM
      AU 2006299449         A1    20070412     AU 2006-299449           20061002
      CA 2624170            A1    20070412     CA 2006-2624170          20061002
      EP 1928476            A1    20080611     EP 2006-816101           20061002
           R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
              IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR
      GB 2446077            A     20080730     GB 2008-6896             20061002
      DE 112006002618       T5    20080828     DE 2006-112006002618     20061002
      JP 2009510126         T     20090312     JP 2008-533776           20061002
      MX 2008004158         A     20080519     MX 2008-4158             20080327
      IN 2008DN02620        A     20080704     IN 2008-DN2620           20080328
      KR 2008059265         A     20080626     KR 2008-710227           20080428
```

CN 101316601	A	20081203	CN 2006-80044248	20080527
US 20090155370	A1	20090618	US 2008-88625	20080930
PRIORITY APPLN. INFO.:			US 2005-723073P	P 20050930
			WO 2006-US38602	W 20061002

AB The invention provides methods and compns. for the treatment of ion imbalances using core-shell composites and compns. comprising such core-shell composites. In particular, the invention provides core-shell particles and compns. comprising potassium binding polymers, and core-shell particles and compns. comprising sodium binding polymers, and in each case, pharmaceutical compns. thereof. Methods of use of the polymeric and pharmaceutical compns. for therapeutic and/or prophylactic benefits are also disclosed. The compns. and methods of the invention offer improved approaches for treatment of hyperkalemia and other indications related to potassium ion homeostasis, and for treatment of hypertension and other indicates related to sodium ion homeostasis.

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER:	2007:209801 CAPLUS <<LOGINID::20090707>>
DOCUMENT NUMBER:	146:428059
TITLE:	Copolymers of .epsilon.-caprolactone and quaternized .epsilon.-caprolactone as gene carriers
AUTHOR(S):	Vroman, Benoit; Mazza, Michael; Fernandez, Manuela R.; Jerome, Robert; Preat, Veronique
CORPORATE SOURCE:	Unite de Pharmacie Galenique, Universite Catholique de Louvain, Brussels, 1200, Belg.
SOURCE:	Journal of Controlled Release (2007), 118(1), 136-144 CODEN: JCREEC; ISSN: 0168-3659
PUBLISHER:	Elsevier B.V.
DOCUMENT TYPE:	Journal
LANGUAGE:	English

AB New copolymers of .epsilon.-caprolactone (CL) and .gamma.-bromo-.epsilon.-caprolactone ***quaternized*** by pyridine (Py + CL) were investigated as non-viral vectors for gene delivery. Copolymers with two molar compns. (50 Py + CL/50 CL and 80 Py + CL/20 CL), each with a diblock or a random structure, were used to prep. nanoparticulate complexes with DNA. Av. size and surface charge of the complexes and extent of the complexation were measured. The DNA condensation by the copolymers was analyzed by a gel retardation assay. Cytotoxicity and transfection efficiency of the copolymers were also evaluated in HeLa cells and compared with ***polyethylenimine*** 50 kDa. The size of the polyplexes was approx. 200 nm The zeta potential first increased with the copolymer/DNA charge ratio and became pos. for charge ratios in the 2-4 range depending on the type of copolymer. DNA was completely condensed within the nanoparticles and the degree of interaction was very high. Cytotoxicity and transfection efficiency were found to be comparable to ***polyethylenimine*** 50 kDa. The exptl. results suggest that the novel copolymers can be used as novel gene delivery vectors.

REFERENCE COUNT: 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER:	2004:267381 CAPLUS <<LOGINID::20090707>>
DOCUMENT NUMBER:	140:309343
TITLE:	Oral ***drug*** ***delivery*** systems for poorly soluble drugs using amphiphilic polyethylenimine polymers with solubilizing and absorption enhancing properties
INVENTOR(S):	Uchegbu, Ijeoma; Schatzlein, Andreas; Cheng, Wei Ping
PATENT ASSIGNEE(S):	The University of Strathclyde, UK; The University Court of the University of Glasgow

SOURCE: PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004026941	A1	20040401	WO 2003-GB4036	20030922
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2499681	A1	20040401	CA 2003-2499681	20030922
AU 2003267581	A1	20040408	AU 2003-267581	20030922
EP 1543063	A1	20050622	EP 2003-748273	20030922
EP 1543063	B1	20090325		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006500437	T	20060105	JP 2004-537295	20030922
AT 426635	T	20090415	AT 2003-748273	20030922
US 20060148982	A1	20060706	US 2005-528602	20050929

PRIORITY APPLN. INFO.: GB 2002-21942 A 20020920
WO 2003-GB4036 W 20030922

AB This invention relates to the delivery of drugs. In particular, this invention relates to the oral delivery of poorly sol. drugs using novel amphiphilic polymers with both solubilizing and absorption enhancing properties. A polyethylenimine polymer according to the present invention wherein monomeric subunits in accordance with the structure is defined in formula [NHCH2CH2]m[N(Z)2CH2CH2]n[N(CH2CH2NH2)CH2CH2]p[N(Z)(CH2CH2NH2)CH2CH2]q[N(CH2CH2N(R1)(R2)(R3))CH2CH2]u[N(CH2CH2N(R1)(R2)(R3))CH2CH2]v[N(CH2CH2N(A)H)CH2CH2]w[N(Z)(CH2CH2N(A)H)CH2CH2]x[N(CH2CH2N(R1)(R2))CH2CH2]y[N(Z)(CH2CH2N(A)(R1)(R2))CH2CH2] wherein m=0-90%; n=0-100%; p=0-50%; q=0-50%; u=0-50%; v=0-50%; w=0-20%; x=0-20%; y=0-20%; z=0-20%; wherein, m+n+p+q+u+v+w+x+y+z=100%; Z=alkyl, alkenyl, alkynyl, etc; A=alkyl, alkenyl, alkynyl, etc; R1=alkyl, alkenyl, alkynyl, etc; R2=alkyl, alkenyl, alkynyl, etc; R3=alkyl, alkenyl, alkynyl, etc.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2003:423404 CAPLUS <<LOGINID::20090707>>
DOCUMENT NUMBER: 139:154707
TITLE: Polycation liposome-mediated gene transfer in vivo
AUTHOR(S): Matsuura, Mitsuo; Yamazaki, Yukako; Sugiyama, Mayu; Kondo, Masami; Ori, Hidetsugu; Nango, Mamoru; Oku, Naoto
CORPORATE SOURCE: Department of Medical Biochemistry and COE Program in the 21st Century, University of Shizuoka School of Pharmaceutical Sciences, Yada, Shizuoka, Japan
SOURCE: Biochimica et Biophysica Acta, Biomembranes (2003), 1612(2), 136-143
CODEN: BBBMBS; ISSN: 0005-2736
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The polycation liposome (PCL), a recently developed gene transfer system, is simply prepd. by a modification of liposomes with cetylated polyethylenimine (PEI), and shows remarkable transgene efficiency with low cytotoxicity. In the present study, we investigated the applicability of PCLs for in vivo gene transfer, since the PCL-mediated transgene efficiency was found to be maintained in the presence of serum. PCLs composed of dioleoylphosphatidylethanolamine (DOPE) with 5 mol% cetyl PEI (PEI av. mr. wt. 1800), were superior for transfection to those of dipalmitoylphosphatidylcholine (DPPC) and cholesterol (2:1 as molar ratio) with 5 mol% cetyl PEI in vitro, although the latter PCLs were more efficient for gene transfer in vivo. PCL-DNA complexes were injected into mice via a tail or the portal vein, with the DNA being a plasmid encoding green fluorescent protein (GFP) or luciferase; and the expression was monitored qual. or quant., resp. Tail vein injection resulted in high expression of both GFP and luciferase genes in lung, and portal vein injection resulted in high expression of both genes in the liver. Concerning the gene delivery efficiency, the PCL was found to be superior to PEI or cetyl PEI alone. The optimal conditions for in vivo transfection with PCLs were also examd.

REFERENCE COUNT: 47 THERE ARE 47 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1997:385627 CAPLUS <<LOGINID::20090707>>
DOCUMENT NUMBER: 127:8941
ORIGINAL REFERENCE NO.: 127:1801a,1804a
TITLE: Cosmetic and pharmaceutical emulsions containing cationic polymers
INVENTOR(S): Ansmann, Achim; Stoll, Gerhard; Fabry, Bernd
PATENT ASSIGNEE(S): Henkel Kgaa, Germany
SOURCE: Ger. Offen., 6 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19542139	A1	19970515	DE 1995-19542139	19951111
DE 19542139	C2	19980730		
EP 776657	A2	19970604	EP 1996-117640	19961104
EP 776657	A3	19970730		
EP 776657	B1	20030326		
R: DE, ES, FR, IT				
ES 2193220	T3	20031101	ES 1996-117640	19961104

PRIORITY APPLN. INFO.: DE 1995-19542139 A 19951111
OTHER SOURCE(S): MARPAT 127:8941

AB Cosmetic and pharmaceutical emulsions contg. C16-22-alkyl oligoglucosides 10-50, C16-22 fatty alcs. 50-90, and cationic polymer 0.1-10 wt.% are highly stable during storage at elevated temps. The cationic polymer may be a cellulose deriv., cationic starch, diallylammonium salt/acrylamide copolymer, ***quaternized*** vinylpyrrolidone/vinylimidazole copolymer, polyglycol-amine condensation product, ***quaternized*** protein or polypeptide, ***polyethylenimine*** , etc. Thus, an emulsion contg. hexadecyl polyglucose 1.9, hexadecyl alc. 3.0, lauryldimoniumhydroxypropyl hydrolyzed collagen 0.1, dicapryl ether 15, decyl oleate 10, almond oil 5, and water to 100 wt.% had a viscosity (in mPa) of 9.800 immediately after prepn. and 9.800 and 9.500 after storage for 7 days at 20.degree. or 40.degree., resp.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=>
=> logoff hold
COST IN U.S. DOLLARS                                  SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                     219.81     274.49

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)            SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                     -18.04     -18.04

 SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 14:50:55 ON 07 JUL 2009
```